.

Make Better Decisions

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

McKesson
Teva
Merck
Express Scripts
AstraZeneca
Cantor Fitzgerald
Boehringer Ingelheim
Citi
Federal Trade Commission
Cipla

Generated: December 17, 2017

DrugPatentWatch Database Preview

Pierre Fabre Derma Company Profile

« Back to Dashboard

What is the competitive landscape for PIERRE FABRE DERMA, and when can generic versions of PIERRE FABRE DERMA drugs launch?

PIERRE FABRE DERMA has one approved drug.

There is one US patent protecting PIERRE FABRE DERMA drugs.

There are thirty-eight patent family members on PIERRE FABRE DERMA drugs in thirty countries.

Summary for Pierre Fabre Derma

International Patents:38
US Patents:1
Tradenames:1
Ingredients:1
NDAs:1
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Pierre Fabre DermaHEMANGEOLpropranolol hydrochlorideSOLUTION;ORAL205410-001Mar 14, 2014RXYesYes► Subscribe► Subscribe► Subscribe
Pierre Fabre DermaHEMANGEOLpropranolol hydrochlorideSOLUTION;ORAL205410-001Mar 14, 2014RXYesYes► Subscribe► Subscribe► Subscribe
Pierre Fabre DermaHEMANGEOLpropranolol hydrochlorideSOLUTION;ORAL205410-001Mar 14, 2014RXYesYes► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Pierre Fabre Derma

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,987,262Use of a beta blocker for the manufacture of a medicament for the treatment of hemangiomas► Subscribe
9,173,858Use of a beta blocker for the manufacture of a medicament for the treatment of hemangiomas► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Pierre Fabre Derma Drugs

Country Document Number Estimated Expiration
Taiwan200932207► Subscribe
Slovenia2187878► Subscribe
New Zealand584307► Subscribe
South Korea101562627► Subscribe
Tunisia2010000170► Subscribe
Japan2011500661► Subscribe
South Korea20150110827► Subscribe
Portugal2233135► Subscribe
Spain2390534► Subscribe
Panama8799401► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Daiichi Sankyo
US Army
Deloitte
Baxter
Johnson and Johnson
Cantor Fitzgerald
Medtronic
Federal Trade Commission
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot